US5961974A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
US7405270B2
(en)
*
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
US7070777B1
(en)
|
1991-11-15 |
2006-07-04 |
The Trustees Of Columbia University In The City Of New York |
Method for inhibiting inflammation with an antibody that binds the 5C8 protein
|
US5474771A
(en)
|
1991-11-15 |
1995-12-12 |
The Trustees Of Columbia University In The City Of New York |
Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
|
CA2089229C
(en)
|
1992-02-14 |
2010-04-13 |
Alejandro A. Aruffo |
Cd40cr receptor and ligands therefor
|
US5925351A
(en)
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
US6001358A
(en)
*
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
US6340459B1
(en)
|
1995-12-01 |
2002-01-22 |
The Trustees Of Columbia University In The City Of New York |
Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
|
ATE219376T1
(de)
*
|
1996-03-20 |
2002-07-15 |
Bristol Myers Squibb Co |
Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
|
NZ337073A
(en)
*
|
1997-01-10 |
2001-01-26 |
Biogen Inc |
use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
|
CN1572325A
(zh)
*
|
1997-01-10 |
2005-02-02 |
拜奥根Idec马萨诸塞公司 |
用抗cd40l化合物治疗狼疮性肾炎
|
EP1754490A3
(en)
|
1997-06-20 |
2010-01-20 |
Biogen Idec MA Inc. |
CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
|
JP2002507967A
(ja)
*
|
1997-06-20 |
2002-03-12 |
パンゲネチックス・ベー・ファウ |
疾病治療のための抗cd40lイムノトキシン
|
AU8266798A
(en)
*
|
1997-06-27 |
1999-01-19 |
Biogen, Inc. |
Cd154 blockade therapy for autoimmune diseases
|
US7060667B1
(en)
|
1998-01-30 |
2006-06-13 |
Biogen Idec Ma, Inc. |
Treatment of follicular lymphomas using inhibitors of the LT pathway
|
CN100352497C
(zh)
*
|
1998-04-03 |
2007-12-05 |
达特茅斯学院理事 |
应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫
|
DE69926647T2
(de)
*
|
1998-10-16 |
2006-11-09 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen
|
US6927203B1
(en)
*
|
1999-08-17 |
2005-08-09 |
Purdue Research Foundation |
Treatment of metastatic disease
|
US7192698B1
(en)
*
|
1999-08-17 |
2007-03-20 |
Purdue Research Foundation |
EphA2 as a diagnostic target for metastatic cancer
|
FR2798386B1
(fr)
|
1999-09-10 |
2003-04-25 |
Didier Raoult |
Oligonucleotides monocatenaires, sondes, amorces et procede de detection des spirochetes
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
DE19962583A1
(de)
*
|
1999-12-23 |
2001-06-28 |
Mueller Hermelink Hans Konrad |
Antikörper gegen Plasmazellen
|
GB0006398D0
(en)
*
|
2000-03-16 |
2000-05-03 |
Novartis Ag |
Organic compounds
|
AU2001251612A1
(en)
|
2000-04-14 |
2001-10-30 |
Millennium Pharmaceuticals, Inc. |
Roles of jak/stat family members in tolerance induction
|
CA2408691A1
(en)
|
2000-05-12 |
2001-11-22 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for achieving immune suppression
|
CA2413190C
(en)
|
2000-07-03 |
2009-04-07 |
Bristol-Myers Squibb Company |
Methods for treating rheumatic diseases using a soluble ctla4 molecule
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
EP1710582A3
(en)
*
|
2000-08-04 |
2006-11-02 |
Ludwig Institute For Cancer Research |
Suppressor genes
|
EP1314037A2
(en)
*
|
2000-09-01 |
2003-05-28 |
Biogen, Inc. |
Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins
|
US7101976B1
(en)
|
2000-09-12 |
2006-09-05 |
Purdue Research Foundation |
EphA2 monoclonal antibodies and methods of making and using same
|
KR100927261B1
(ko)
*
|
2001-01-17 |
2009-11-18 |
트루비온 파마슈티칼스, 인코포레이티드 |
결합 도메인-면역글로불린 융합 단백질
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2008200400B2
(en)
*
|
2001-01-17 |
2012-06-07 |
Aptevo Research And Development Llc |
Binding domain-immunoglobulin fusion proteins
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
EP1397153B1
(en)
|
2001-05-23 |
2008-04-02 |
Bristol-Myers Squibb Company |
Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
|
EP2075256A2
(en)
|
2002-01-14 |
2009-07-01 |
William Herman |
Multispecific binding molecules
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
PT1517921E
(pt)
*
|
2002-06-28 |
2006-09-29 |
Domantis Ltd |
Ligandos duplamente especificos com semi-vida no soro aumentada
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
US7563443B2
(en)
*
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
US8993319B2
(en)
*
|
2004-12-28 |
2015-03-31 |
Innate Pharma S.A. |
Monoclonal antibodies against NKG2A
|
ATE485057T1
(de)
|
2005-05-26 |
2010-11-15 |
Seattle Genetics Inc |
Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
|
EP2298815B1
(en)
*
|
2005-07-25 |
2015-03-11 |
Emergent Product Development Seattle, LLC |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
WO2007114319A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
抗体の血中動態を制御する方法
|
UA100116C2
(ru)
|
2006-06-08 |
2012-11-26 |
Чугей Сейяку Кабусики Кайся |
Профилактика или лечение воспалительного заболевания
|
WO2007146968A2
(en)
*
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
PT2038306E
(pt)
|
2006-06-30 |
2015-03-02 |
Novo Nordisk As |
Anticorpos anti-nkg2a e utilizações dos mesmos
|
KR20090071652A
(ko)
|
2006-10-20 |
2009-07-01 |
바이오겐 아이덱 엠에이 인코포레이티드 |
가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
|
US8338376B2
(en)
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
IL199534A
(en)
|
2007-01-05 |
2013-01-31 |
Univ Zuerich |
An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
|
CN103408661B
(zh)
*
|
2007-01-05 |
2016-04-06 |
苏黎世大学 |
提供疾患特异性结合分子和靶的方法
|
RU2510400C9
(ru)
|
2007-09-26 |
2014-07-20 |
Чугаи Сейяку Кабусики Кайся |
Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
|
TWI464262B
(zh)
|
2007-09-26 |
2014-12-11 |
中外製藥股份有限公司 |
抗體固定區的變異
|
US20090123946A1
(en)
*
|
2007-10-19 |
2009-05-14 |
Abbott Laboratories |
Immunoassays and kits for the detection of ngal
|
US20090124022A1
(en)
*
|
2007-10-19 |
2009-05-14 |
Abbott Laboratories |
Antibodies that bind to mammalian ngal and uses thereof
|
US8846036B2
(en)
*
|
2007-10-19 |
2014-09-30 |
Abbott Laboratories |
Antibodies that bind to mammalian NGAL and uses thereof
|
TWI441649B
(zh)
|
2007-12-05 |
2014-06-21 |
Chugai Pharmaceutical Co Ltd |
Use of anti-NR10 monoclonal antibody with neutralizing activity against NR10 in the manufacture of prophylactic or therapeutic agents for pruritus
|
RU2531521C2
(ru)
|
2007-12-05 |
2014-10-20 |
Чугаи Сейяку Кабусики Кайся |
Антитело против nr10 и его применение
|
JP5774312B2
(ja)
*
|
2008-01-24 |
2015-09-09 |
ノボ・ノルデイスク・エー/エス |
ヒト化抗ヒトnkg2aモノクローナル抗体
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
CN102056946A
(zh)
|
2008-04-11 |
2011-05-11 |
中外制药株式会社 |
与多个分子的抗原反复结合的抗原结合分子
|
JP5573156B2
(ja)
*
|
2008-07-10 |
2014-08-20 |
東レ株式会社 |
癌の治療及び予防用医薬組成物
|
WO2010036851A2
(en)
*
|
2008-09-26 |
2010-04-01 |
Wyeth Llc |
Single chain antibody library design
|
JP2012511014A
(ja)
|
2008-12-05 |
2012-05-17 |
エイエルエス・セラピー・デベロップメント・インスティテュート |
神経変成疾患を治療する方法
|
KR20160062207A
(ko)
*
|
2008-12-05 |
2016-06-01 |
추가이 세이야쿠 가부시키가이샤 |
항nr10 항체 및 그의 이용
|
JP5139517B2
(ja)
*
|
2008-12-05 |
2013-02-06 |
中外製薬株式会社 |
抗nr10抗体、およびその利用
|
JP2010210772A
(ja)
*
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
EP3674317A1
(en)
|
2009-03-19 |
2020-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
KR102568454B1
(ko)
|
2010-11-30 |
2023-08-18 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
DK2710033T3
(da)
|
2011-05-17 |
2021-03-08 |
Univ Rockefeller |
Human immundefektvirus-neutraliserende antistoffer og fremgangsmåder til anvendelse deraf
|
KR102047248B1
(ko)
|
2011-06-17 |
2019-11-21 |
노보 노르디스크 에이/에스 |
침식성 세포의 선택적 제거
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
KR101637915B1
(ko)
|
2011-10-13 |
2016-07-11 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd40l을 길항하는 항체 폴리펩티드
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
WO2016167263A1
(ja)
|
2015-04-14 |
2016-10-20 |
中外製薬株式会社 |
Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
|
SG10202002577XA
(en)
|
2015-09-21 |
2020-04-29 |
Aptevo Res & Development Llc |
Cd3 binding polypeptides
|
EP3565596A4
(en)
|
2017-01-05 |
2020-12-16 |
Brown University |
PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
|
MA49947B1
(fr)
|
2017-08-22 |
2023-03-31 |
Biogen Ma Inc |
Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
|
US10766968B2
(en)
|
2017-08-23 |
2020-09-08 |
Brown University |
Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
|
CN108484761B
(zh)
*
|
2018-03-10 |
2021-04-30 |
吉林大学 |
一种特异性识别并诱导Aβ42的寡聚体及原纤维解聚的单链抗体、单链抗体基因及其应用
|
CN110950953B
(zh)
*
|
2018-09-26 |
2022-05-13 |
福州拓新天成生物科技有限公司 |
抗b7-h3的单克隆抗体及其在细胞治疗中的应用
|
KR102142499B1
(ko)
*
|
2019-09-11 |
2020-08-10 |
재단법인 오송첨단의료산업진흥재단 |
Ykl-40 표적 인간 단일클론항체
|
KR102416078B1
(ko)
|
2019-11-20 |
2022-07-01 |
추가이 세이야쿠 가부시키가이샤 |
항체 함유 제제
|